CLAIMS

1. A pharmaceutical composition with an improved injection site toleration comprising a therapeutically effective amount of a neurokinin receptor (NK-1) antagonist with a pharmaceutically acceptable cyclodextrin.

2. A pharmaceutical composition according to Claim 1 wherein the antagonist is selected from the group consisting of piperazine compounds, spiro-substituted azacycles, dialkyline piperadino compounds, trypthophan urea, polycyclic amine compounds, substituted arylaliphatic compounds, aromatic amine compounds, quaternary ammonium salts or aromatic amine compounds, aryl-substituted heterocycles, polycyclicamine compounds, substituted aryl piperazines, carboxamide derivatives, and bis-piperadinyl non-peptidal compounds, or salts thereof.

3. The pharmaceutical composition of Claim 1 or Claim 2 wherein the NK-1 antagonist is a compound of Formula I,



I

or pharmaceutically acceptable salt or prodrug thereof, wherein R^2 is selected from the group consisting of methyl, ethyl, isopropyl, *sec*-butyl and *tert*-butyl.

4. A pharmaceutical composition according to claim 3 wherein the compound of Formula I is a compound of Formula Ia,



Ia

or a pharmaceutically acceptable salt or prodrug thereof.

5. The pharmaceutical composition according to Claims 1, 2, 3 or 4 wherein the cyclodextrin is selected from β-cyclodextrin, hydroxypropyl β-cyclodextrin, sulfobutylether β-cyclodextrin or substituted cyclodextrins.

6. The pharmaceutical composition according to any preceding claim wherein the cyclodextrin is about 2% to about 40% of the composition.

7. A pharmaceutical composition according to any preceding claim wherein the therapeutically effective amount of the NK-1 antagonist is 0.01 mg/kg to 100 mg/kg of a patient's body weight.

8. The pharmaceutical composition according to any preceding claim for use as a medicament.

9. The use of a composition according to any of claims 1 to 7 in the manufacture of a medicament for the treatment of a disease for which a NK-1 antagonist is indicated.

10. A method for the treatment of a disease for which a NK-1 antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of any of Claims 1 to 7.